Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ANG-3070 in Healthy Adults
NCT04196179Phase 1Completed
- Sponsor
- Angion Biomedica Corp.
- Start
- Dec 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ansornitinib in idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) (2 arms), sponsored by Angion Biomedica Corp. Primary endpoints: Difference in Adverse Events, Difference in Vital Signs and 3 more. Started Dec 2019; status: completed.
02
Drugs
ansornitinib
03
Conditions
idiopathic pulmonary fibrosis (IPF)focal segmental glomerulosclerosis (FSGS)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04196179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04196179.